368 related articles for article (PubMed ID: 28413972)
1. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
2. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
3. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
4. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
5. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
Gavin AR; Struthers AD
Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
Berry CE; Hare JM
J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
[TBL] [Abstract][Full Text] [Related]
7. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
8. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia and cardiovascular disease risk.
Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
[TBL] [Abstract][Full Text] [Related]
10. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
11. Allopurinol as a therapeutic option in cardiovascular disease.
Okafor ON; Farrington K; Gorog DA
Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
[TBL] [Abstract][Full Text] [Related]
12. Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase.
Sekine M; Okamoto K; Ichida K
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829959
[TBL] [Abstract][Full Text] [Related]
13. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.
Higgins P; Dawson J; Lees KR; McArthur K; Quinn TJ; Walters MR
Cardiovasc Ther; 2012 Aug; 30(4):217-26. PubMed ID: 22099531
[TBL] [Abstract][Full Text] [Related]
14. Reducing effect of mangiferin on serum uric acid levels in mice.
Niu Y; Lu W; Gao L; Lin H; Liu X; Li L
Pharm Biol; 2012 Sep; 50(9):1177-82. PubMed ID: 22881143
[TBL] [Abstract][Full Text] [Related]
15. Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
Niu Y; Liu J; Liu HY; Gao LH; Feng GH; Liu X; Li L
Pharm Biol; 2016 Sep; 54(9):1680-6. PubMed ID: 26916555
[TBL] [Abstract][Full Text] [Related]
16. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
17. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
18. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
[TBL] [Abstract][Full Text] [Related]
19. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
20. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
